Adults living with idiopathic hypersomnia and narcolepsy type 1 often report cognitive difficulties, including problems with memory, attention, and mental fatigue. However, new research published in ...
The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive ...
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate ...
Risk for cardiovascular disease was significantly increased in patients with narcolepsy, highlighting the importance of routine screening in this population. Patients with narcolepsy have a ...
A hormone produced by the brain, orexin, may play a central role in the functioning of the brain’s glymphatic system, which clears waste, according to a new study from the University of Oulu.
Axsome Therapeutics said U.S. health regulators have supported the company's application for its narcolepsy treatment. The biopharmaceutical company said Wednesday that it was provided with formal pre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results